Bio-Techne (NASDAQ:TECH) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.
Insider & Institutional Ownership
93.8% of Bio-Techne shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 3.8% of Bio-Techne shares are held by insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.
Valuation & Earnings
This table compares Bio-Techne and Allogene Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Bio-Techne has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
This table compares Bio-Techne and Allogene Therapeutics’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current ratings and recommmendations for Bio-Techne and Allogene Therapeutics, as reported by MarketBeat.com.
||Strong Buy Ratings
Bio-Techne presently has a consensus target price of $367.50, suggesting a potential downside of 13.27%. Allogene Therapeutics has a consensus target price of $52.08, suggesting a potential upside of 49.79%. Given Allogene Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Bio-Techne.
Bio-Techne beats Allogene Therapeutics on 8 of the 13 factors compared between the two stocks.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.